REGENERON PHARMACEUTICALS, INC.
Ticker: REGNHealthcarePharmaceutical PreparationsS&P 500The business
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for patients with serious diseases. The company operates through a diversified portfolio spanning ophthalmology, immunology and inflammation, oncology, hematology, cardiovascular and metabolic diseases, neurology, and rare diseases. Regeneron's website is www.regeneron.com.
The company's marketed products include EYLEA and EYLEA HD for retinal diseases, Dupixent for allergic and inflammatory conditions, Libtayo for various cancers, Praluent for cardiovascular risk reduction, Kevzara for rheumatoid arthritis, and numerous other approved therapeutics. In 2025, Regeneron reported total revenues of approximately $14.3 billion with net income of $4.5 billion. The company maintains a robust pipeline of product candidates in clinical development across multiple therapeutic areas, with several programs in Phase 2 and Phase 3 trials.
Regeneron's core competitive advantages stem from its proprietary technology platforms, particularly VelociSuite, which encompasses VelocImmune, VelociGene, VelociMouse, VelociMab, and related technologies for discovering and developing fully human antibodies and bispecific antibodies. The company also operates the Regeneron Genetics Center, a subsidiary leveraging de-identified genomic and clinical data from over three million sequenced samples to identify novel therapeutic targets and validate genetic associations.
The company maintains significant strategic collaborations with major pharmaceutical partners. Sanofi collaborates on the global development and commercialization of Dupixent, Kevzara, and itepekimab, while Bayer partners on EYLEA development and commercialization outside the United States. Regeneron also collaborates with Alnylam Pharmaceuticals on RNAi therapeutics and with Intellia Therapeutics on CRISPR/Cas9 gene-editing technology.
Regeneron operates as an accelerated filer with the Securities and Exchange Commission and maintains manufacturing and commercial capabilities alongside its research and development operations. The company's business model emphasizes maintaining a strong scientific research foundation while building integrated clinical development, manufacturing, and commercial capabilities to advance innovative medicines to patients globally.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- HQ
- TARRYTOWN, NY
- FY end
- 12-31
- CIK
- 872589
- SIC
- 2834
Ownership
Who holds REGENERON PHARMACEUTICALS, INC. — across funds, superinvestors and bonds · N-PORT 2026Q2 · 13F 2026-06-30
Top fund holders
| Fund | % of fund | Value |
|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI · VANGUARD INDEX FUNDS | 0.09% | $2.04B |
| Dodge & Cox Stock Fund DODGX · Dodge & Cox Funds | 1.64% | $1.95B |
| VANGUARD 500 INDEX FUND VOO · VANGUARD INDEX FUNDS | 0.10% | $1.61B |
| Invesco QQQ Trust, Series 1 QQQ | 0.28% | $1.36B |
| iShares Core S&P 500 ETF IVV · iShares Trust | 0.10% | $856.96M |
Bonds held by funds
Funds report holding 2 issues of REGENERON PHARMACEUTICALS, INC.'s debt, $257.23M at fund-held market value — what funds hold, not the company's debt outstanding. Weighted-average coupon 2.04%, maturing 2030–2050.
| Issue | Coupon | Matures | Funds | Fund-held |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc | 1.750% | 2030-09-15 | 95 | $187.14M |
| Regeneron Pharmaceuticals Inc | 2.800% | 2050-09-15 | 58 | $70.09M |
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Go deeper in your own AI
15 years of statements, narrative and filings — queryable over MCP.
Professionals can also use the built-in AI chat (subscription + your own Anthropic key).
15 years of REGENERON PHARMACEUTICALS, INC.'s financials
Income statement, balance sheet and cash flow across 15 years, every filing with its disclosures, and each number traceable to the filing it came from — free with an account, no card required.
Sign in free